Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
November 3, 2003
- BULLETIN
November 3, 2003
- MEDICAL DEVICE NEWS IN BRIEF
November 3, 2003
- Licensing is "Life or Death Issue" for Drug Makers: JPLA Seminar
November 3, 2003
- Council on Early-morning, Late-night Drug Sales Holds 1st Meeting
November 3, 2003
- BUSINESS NEWS IN BRIEF
November 3, 2003
- Safety, Convenience Are Both Rights of Consumers: JACDS
November 3, 2003
- Drug Cost Ratio Hits Record Low, 21.6% in 2002
November 3, 2003
- Victims of Drug-induced Health Damage Firmly Opposed to Sales Deregulation
November 3, 2003
- Drug Production Value Fell 0.2% in 2002
November 3, 2003
- DIAGNOSTIC NEWS IN BRIEF
November 3, 2003
- HPB, HSB Notify Prefectures on Expected Supplies of Influenza Drugs
November 3, 2003
- Council Announces 4-tier Priority Ranking for Science, Technology Budgets
November 3, 2003
- REGULATORY NEWS IN BRIEF
November 3, 2003
- Shimoina Kousei Hospital Issuing Generic-name Prescriptions
November 3, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 3, 2003
- WORLD NEWS IN BRIEF
November 3, 2003
- Iryo Proverbs Reveal Japanese Spirit (14)
November 3, 2003
- Import Approval for Evista, Precedex Recommended
October 27, 2003
- Pricing of Long-listed Drugs Discussed by Chuikyo Subpanel
October 27, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…